-
1
-
-
0242669907
-
Costs of prostate cancer, metastatic to the bone, in the Netherlands
-
M. T. Groot, C. G. G. B. Kruger, R. C. M. Pelger, and C. A. Uylde Groot, "Costs of prostate cancer, metastatic to the bone, in the Netherlands, " European Urology, vol. 43, no. 3, pp. 226-232, 2003.
-
(2003)
European Urology
, vol.43
, Issue.3
, pp. 226-232
-
-
Groot, M.T.1
Kruger, C.G.G.B.2
Pelger, R.C.M.3
Uylde Groot, C.A.4
-
2
-
-
84891809097
-
EAU guidelines on prostate cancer. Part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer
-
A. Heidenreich, P. J. Bastian, J. Bellmunt et al., "EAU guidelines on prostate cancer. Part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer, " European Urology, vol. 65, no. 2, pp. 467-479, 2014.
-
(2014)
European Urology
, vol.65
, Issue.2
, pp. 467-479
-
-
Heidenreich, A.1
Bastian, P.J.2
Bellmunt, J.3
-
3
-
-
84890430333
-
Cancer-associated bone disease
-
R. Rizzoli, J.-J. Body, M.-L. Brandi et al., "Cancer-associated bone disease, " Osteoporosis International, vol. 24, no. 12, pp. 2929-2953, 2013.
-
(2013)
Osteoporosis International
, vol.24
, Issue.12
, pp. 2929-2953
-
-
Rizzoli, R.1
Body, J.-J.2
Brandi, M.-L.3
-
4
-
-
84857957486
-
Bone health management in prostate cancer patients receiving androgen deprivation therapy
-
V. Dhanapal and D. J. Reeves, "Bone health management in prostate cancer patients receiving androgen deprivation therapy, " Journal of Oncology Pharmacy Practice, vol. 18, no. 1, pp. 84-90, 2012.
-
(2012)
Journal of Oncology Pharmacy Practice
, vol.18
, Issue.1
, pp. 84-90
-
-
Dhanapal, V.1
Reeves, D.J.2
-
5
-
-
33748280677
-
Changing patterns of pelvic lymphadenectomy for prostate cancer: Results from CaPSURE
-
J. Kawakami, M. V. Meng, N. Sadetsky, D. M. Latini, J. Duchane, and P. R. Carroll, "Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE, " Journal of Urology, vol. 176, no. 4, pp. 1382-1386, 2006.
-
(2006)
Journal of Urology
, vol.176
, Issue.4
, pp. 1382-1386
-
-
Kawakami, J.1
Meng, M.V.2
Sadetsky, N.3
Latini, D.M.4
Duchane, J.5
Carroll, P.R.6
-
6
-
-
84901626754
-
Endocrine aspects of bone metastases
-
L. C. Hofbauer, T. D. Rachner, R. E. Coleman, and F. Jakob, "Endocrine aspects of bone metastases, " The Lancet Diabetes and Endocrinology, vol. 2, no. 6, pp. 500-512, 2014.
-
(2014)
The Lancet Diabetes and Endocrinology
, vol.2
, Issue.6
, pp. 500-512
-
-
Hofbauer, L.C.1
Rachner, T.D.2
Coleman, R.E.3
Jakob, F.4
-
7
-
-
84884411754
-
Androgens and prostate cancer; Pathogenesis and deprivation therapy
-
M. Grossmann, A. S. Cheung, and J. D. Zajac, "Androgens and prostate cancer; Pathogenesis and deprivation therapy, " Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 27, no. 4, pp. 603-616, 2013.
-
(2013)
Best Practice and Research: Clinical Endocrinology and Metabolism
, vol.27
, Issue.4
, pp. 603-616
-
-
Grossmann, M.1
Cheung, A.S.2
Zajac, J.D.3
-
8
-
-
84864799616
-
Male osteoporosis
-
M. T. Drake and S. Khosla, "Male osteoporosis, " Endocrinology andMetabolismClinics ofNorthAmerica, vol. 41, no. 3, pp. 629-641, 2012.
-
(2012)
Endocrinology AndMetabolismClinics OfNorthAmerica
, vol.41
, Issue.3
, pp. 629-641
-
-
Drake, M.T.1
Khosla, S.2
-
9
-
-
84864283300
-
Muscles, exercise and obesity: Skeletal muscle as a secretory organ
-
B. K. Pedersen and M. A. Febbraio, "Muscles, exercise and obesity: skeletal muscle as a secretory organ, " Nature Reviews Endocrinology, vol. 8, no. 8, pp. 457-465, 2012.
-
(2012)
Nature Reviews Endocrinology
, vol.8
, Issue.8
, pp. 457-465
-
-
Pedersen, B.K.1
Febbraio, M.A.2
-
10
-
-
84907482751
-
Muscle and bone effects of androgen deprivation therapy: Current and emerging therapies
-
A. S. Cheung, J. D. Zajac, andM. Grossmann, "Muscle and bone effects of androgen deprivation therapy: current and emerging therapies, " Endocrine Related Cancer, vol. 21, no. 5, pp. R371-R394, 2014.
-
(2014)
Endocrine Related Cancer
, vol.21
, Issue.5
, pp. R371-R394
-
-
Cheung, A.S.1
Zajac, J.D.2
Grossmann, M.3
-
11
-
-
69049105440
-
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
-
M. R. Smith, B. Egerdie, N. H. Toriz et al., "Denosumab in men receiving androgen-deprivation therapy for prostate cancer, " The New England Journal of Medicine, vol. 361, no. 8, pp. 745-755, 2009.
-
(2009)
The New England Journal of Medicine
, vol.361
, Issue.8
, pp. 745-755
-
-
Smith, M.R.1
Egerdie, B.2
Toriz, N.H.3
-
12
-
-
84857042883
-
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: A systematic review and metaanalysis
-
A. Serpa Neto, M. Tobias-Machado, M. A. P. Esteves et al., "Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and metaanalysis, " Prostate Cancer and Prostatic Diseases, vol. 15, no. 1, pp. 36-44, 2012.
-
(2012)
Prostate Cancer and Prostatic Diseases
, vol.15
, Issue.1
, pp. 36-44
-
-
Serpa Neto, A.1
Tobias-Machado, M.2
Esteves, M.A.P.3
-
13
-
-
79953751008
-
Osteoporosis: Now and the future
-
T. D. Rachner, S. Khosla, and L. C. Hofbauer, "Osteoporosis: now and the future, " The Lancet, vol. 377, no. 9773, pp. 1276-1287, 2011.
-
(2011)
The Lancet
, vol.377
, Issue.9773
, pp. 1276-1287
-
-
Rachner, T.D.1
Khosla, S.2
Hofbauer, L.C.3
-
14
-
-
84896130208
-
Dickkopf-1 as a mediator and novel target in malignant bone disease
-
T. D. Rachner, A. Göbel, P. Benad-Mehner, L. C. Hofbauer, and M. Rauner, "Dickkopf-1 as a mediator and novel target in malignant bone disease, " Cancer Letters, vol. 346, no. 2, pp. 172-177, 2014.
-
(2014)
Cancer Letters
, vol.346
, Issue.2
, pp. 172-177
-
-
Rachner, T.D.1
Göbel, A.2
Benad-Mehner, P.3
Hofbauer, L.C.4
Rauner, M.5
-
15
-
-
84893044528
-
Romosozumab in postmenopausal women with low bone mineral density
-
M. R. McClung, A. Grauer, S. Boonen et al., "Romosozumab in postmenopausal women with low bone mineral density, " The New England Journal of Medicine, vol. 370, no. 5, pp. 412-420, 2014.
-
(2014)
The New England Journal of Medicine
, vol.370
, Issue.5
, pp. 412-420
-
-
McClung, M.R.1
Grauer, A.2
Boonen, S.3
-
16
-
-
84899099995
-
Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids
-
B. Garcá-Fontana, S. Morales-Santana, M. Varsavsky et al., "Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids, " Osteoporosis International, vol. 25, no. 2, pp. 645-651, 2014.
-
(2014)
Osteoporosis International
, vol.25
, Issue.2
, pp. 645-651
-
-
Garcá-Fontana, B.1
Morales-Santana, S.2
Varsavsky, M.3
-
17
-
-
71849104052
-
Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation
-
R. R. Gomes Jr., P. Buttke, E. M. Paul, and R. A. Sikes, "Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation, " Clinical and Experimental Metastasis, vol. 26, no. 7, pp. 641-651, 2009.
-
(2009)
Clinical and Experimental Metastasis
, vol.26
, Issue.7
, pp. 641-651
-
-
Gomes, R.R.1
Buttke, P.2
Paul, E.M.3
Sikes, R.A.4
-
18
-
-
84930898587
-
Bone-related parameters are the main prognostic factors for overall survival in men with bonemetastases fromcastration-resistant prostate cancer
-
K. Fizazi, C. Massard, M. Smith et al., "Bone-related parameters are the main prognostic factors for overall survival in men with bonemetastases fromcastration-resistant prostate cancer, " European Urology, 2014.
-
(2014)
European Urology
-
-
Fizazi, K.1
Massard, C.2
Smith, M.3
-
19
-
-
84892442211
-
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event
-
N. M. Hahn, C. T. Yiannoutsos, K. Kirkpatrick, J. Sharma, and C. J. Sweeney, "Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event, " Clinical Genitourinary Cancer, vol. 12, no. 1, pp. 33. e4-40. e4, 2014.
-
(2014)
Clinical Genitourinary Cancer
, vol.12
, Issue.1
, pp. 33e4-40e4
-
-
Hahn, N.M.1
Yiannoutsos, C.T.2
Kirkpatrick, K.3
Sharma, J.4
Sweeney, C.J.5
-
20
-
-
0034659963
-
Biochemical markers and skeletal metastases
-
L. M. Demers, L. Costa, and A. Lipton, "Biochemical markers and skeletal metastases, " Cancer, vol. 88, no. 12, pp. 2919-2926, 2000.
-
(2000)
Cancer
, vol.88
, Issue.12
, pp. 2919-2926
-
-
Demers, L.M.1
Costa, L.2
Lipton, A.3
-
21
-
-
79953329365
-
Niche competition and cancer metastasis to bone
-
L. G. Schuettpelz andD. C. Link, "Niche competition and cancer metastasis to bone, "The Journal of Clinical Investigation, vol. 121, no. 4, pp. 1253-1255, 2011.
-
(2011)
The Journal of Clinical Investigation
, vol.121
, Issue.4
, pp. 1253-1255
-
-
Schuettpelz, L.G.1
Link, C.D.2
-
22
-
-
0029085123
-
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate
-
J. B. Nelson, S. P. Hedican, D. J. George et al., "Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate, " Nature Medicine, vol. 1, no. 9, pp. 944-949, 1995.
-
(1995)
Nature Medicine
, vol.1
, Issue.9
, pp. 944-949
-
-
Nelson, J.B.1
Hedican, S.P.2
George, D.J.3
-
23
-
-
33846624243
-
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation
-
G. A. Clines, K. S. Mohammad, Y. Bao et al., "Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation, " Molecular Endocrinology, vol. 21, no. 2, pp. 486-498, 2007.
-
(2007)
Molecular Endocrinology
, vol.21
, Issue.2
, pp. 486-498
-
-
Clines, G.A.1
Mohammad, K.S.2
Bao, Y.3
-
24
-
-
0141479984
-
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases
-
J. J. Yin, K. S. Mohammad, S. M. Käkönen et al., "A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 19, pp. 10954-10959, 2003.
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.19
, pp. 10954-10959
-
-
Yin, J.J.1
Mohammad, K.S.2
Käkönen, S.M.3
-
25
-
-
84868200731
-
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
-
J. B. Nelson, K. Fizazi, K. Miller et al., "Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone, " Cancer, vol. 118, no. 22, pp. 5709-5718, 2012.
-
(2012)
Cancer
, vol.118
, Issue.22
, pp. 5709-5718
-
-
Nelson, J.B.1
Fizazi, K.2
Miller, K.3
-
26
-
-
84879466638
-
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer
-
K. S. Fizazi, C. S. Higano, J. B. Nelson et al., "Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer, " Journal of Clinical Oncology, vol. 31, no. 14, pp. 1740-1747, 2013.
-
(2013)
Journal of Clinical Oncology
, vol.31
, Issue.14
, pp. 1740-1747
-
-
Fizazi, K.S.1
Higano, C.S.2
Nelson, J.B.3
-
27
-
-
12344291865
-
Bone morphogenetic proteins
-
D. Chen, M. Zhao, and G. R. Mundy, "Bone morphogenetic proteins, " Growth Factors, vol. 22, no. 4, pp. 233-241, 2004.
-
(2004)
Growth Factors
, vol.22
, Issue.4
, pp. 233-241
-
-
Chen, D.1
Zhao, M.2
Mundy, G.R.3
-
28
-
-
24944480253
-
Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism
-
J. Dai, J. Keller, J. Zhang, Y. Lu, Z. Yao, and E. T. Keller, "Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism, " Cancer Research, vol. 65, no. 18, pp. 8274-8285, 2005.
-
(2005)
Cancer Research
, vol.65
, Issue.18
, pp. 8274-8285
-
-
Dai, J.1
Keller, J.2
Zhang, J.3
Lu, Y.4
Yao, Z.5
Keller, E.T.6
-
29
-
-
33847025382
-
Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases
-
R. Schweninger, C. A. Rentsch, A. Wetterwald et al., "Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases, " American Journal of Pathology, vol. 170, no. 1, pp. 160-175, 2007.
-
(2007)
American Journal of Pathology
, vol.170
, Issue.1
, pp. 160-175
-
-
Schweninger, R.1
Rentsch, C.A.2
Wetterwald, A.3
-
30
-
-
0033199111
-
Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone
-
K. Jacob, M. Webber, D. Benayahu, and H. K. Kleinman, "Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone, " Cancer Research, vol. 59, no. 17, pp. 4453-4457, 1999.
-
(1999)
Cancer Research
, vol.59
, Issue.17
, pp. 4453-4457
-
-
Jacob, K.1
Webber, M.2
Benayahu, D.3
Kleinman, H.K.4
-
31
-
-
0346725927
-
Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis
-
J. Rubin, L. W. K. Chung, X. Fan et al., "Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis, " Prostate, vol. 58, no. 1, pp. 41-49, 2004.
-
(2004)
Prostate
, vol.58
, Issue.1
, pp. 41-49
-
-
Rubin, J.1
Chung, L.W.K.2
Fan, X.3
-
32
-
-
84889086250
-
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: A 15-year study in two large US health systems
-
G. Oster, L. Lamerato, A. G. Glass et al., "Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems, " Supportive Care in Cancer, vol. 21, no. 12, pp. 3279-3286, 2013.
-
(2013)
Supportive Care in Cancer
, vol.21
, Issue.12
, pp. 3279-3286
-
-
Oster, G.1
Lamerato, L.2
Glass, A.G.3
-
33
-
-
2942518111
-
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
-
F. Saad, D. M. Gleason, R. Murray et al., "Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, " Journal of the National Cancer Institute, vol. 96, no. 11, pp. 879-882, 2004.
-
(2004)
Journal of the National Cancer Institute
, vol.96
, Issue.11
, pp. 879-882
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
34
-
-
0642337996
-
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer
-
E. J. Small, M. R. Smith, J. J. Seaman, S. Petrone, and M. O. Kowalski, "Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer, " Journal of ClinicalOncology, vol. 21, no. 23, pp. 4277-4284, 2003.
-
(2003)
Journal of ClinicalOncology
, vol.21
, Issue.23
, pp. 4277-4284
-
-
Small, E.J.1
Smith, M.R.2
Seaman, J.J.3
Petrone, S.4
Kowalski, M.O.5
-
35
-
-
0141688330
-
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain
-
D. S. Ernst, I. F. Tannock, E. W. Winquist et al., "Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain, " Journal of Clinical Oncology, vol. 21, no. 17, pp. 3335-3342, 2003.
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.17
, pp. 3335-3342
-
-
Ernst, D.S.1
Tannock, I.F.2
Winquist, E.W.3
-
36
-
-
69149084971
-
Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Longterm overall survival results from the MRC PR04 and PR05 randomised controlled trials
-
D. P. Dearnaley, M. D. Mason, M. K. Parmar, K. Sanders, and M. R. Sydes, "Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: longterm overall survival results from the MRC PR04 and PR05 randomised controlled trials, " The Lancet Oncology, vol. 10, no. 9, pp. 872-876, 2009.
-
(2009)
The Lancet Oncology
, vol.10
, Issue.9
, pp. 872-876
-
-
Dearnaley, D.P.1
Mason, M.D.2
Parmar, M.K.3
Sanders, K.4
Sydes, M.R.5
-
37
-
-
84873268474
-
Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A
-
Y. Cirak, U. Varol, H. Atmaca et al., "Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A, " BJU International, vol. 110, no. 11, pp. E1147-E1154, 2012.
-
(2012)
BJU International
, vol.110
, Issue.11
, pp. E1147-E1154
-
-
Cirak, Y.1
Varol, U.2
Atmaca, H.3
-
38
-
-
84876423480
-
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: Evidence for a role of the mevalonate pathway in disease progression?
-
T. Todenhöfer, J. Hennenlotter, U. Kühs et al., "Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the mevalonate pathway in disease progression?" World Journal of Urology, vol. 31, no. 2, pp. 345-350, 2013.
-
(2013)
World Journal of Urology
, vol.31
, Issue.2
, pp. 345-350
-
-
Todenhöfer, T.1
Hennenlotter, J.2
Kühs, U.3
-
39
-
-
14544291047
-
Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures
-
H. X. Jiang, S. R. Majumdar, D. A. Dick et al., "Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures, " Journal of Bone and Mineral Research, vol. 20, no. 3, pp. 494-500, 2005.
-
(2005)
Journal of Bone and Mineral Research
, vol.20
, Issue.3
, pp. 494-500
-
-
Jiang, H.X.1
Majumdar, S.R.2
Dick, D.A.3
-
40
-
-
79952360832
-
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, doubleblind study
-
K. Fizazi, M. Carducci, M. Smith et al., "Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study, " The Lancet, vol. 377, no. 9768, pp. 813-822, 2011.
-
(2011)
The Lancet
, vol.377
, Issue.9768
, pp. 813-822
-
-
Fizazi, K.1
Carducci, M.2
Smith, M.3
-
41
-
-
84889093279
-
Pain and healthrelated quality of life in patients with advanced solid tumours and bonemetastases: Integrated results fromthree randomized, double-blind studies of denosumab and zoledronic acid
-
R. von Moos, J.-J. Body, B. Egerdie et al., "Pain and healthrelated quality of life in patients with advanced solid tumours and bonemetastases: integrated results fromthree randomized, double-blind studies of denosumab and zoledronic acid, " Supportive Care in Cancer, vol. 21, no. 12, pp. 3497-3507, 2013.
-
(2013)
Supportive Care in Cancer
, vol.21
, Issue.12
, pp. 3497-3507
-
-
Von Moos, R.1
Body, J.-J.2
Egerdie, B.3
-
42
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
C. Parker, S. Nilsson DHeinrich, S. I. Helle et al., "Alpha emitter radium-223 and survival in metastatic prostate cancer, "TheNew England Journal of Medicine, vol. 369, no. 3, pp. 213-223, 2013.
-
(2013)
TheNew England Journal of Medicine
, vol.369
, Issue.3
, pp. 213-223
-
-
Parker, C.1
Nilsson Dheinrich, S.2
Helle, S.I.3
-
43
-
-
84937136684
-
Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the endpoint's definition?
-
B. Tombal, "Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the endpoint's definition?" Annals of Oncology, 2014.
-
(2014)
Annals of Oncology
-
-
Tombal, B.1
-
44
-
-
84937133846
-
Denosumab for the prevention of skeletal complications in metastatic castrationresistant prostate cancer: Comparison of skeletal-related events and symptomatic skeletal events
-
M. R. Smith, R. E. Coleman, L. Klotz et al., "Denosumab for the prevention of skeletal complications in metastatic castrationresistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events, " Annals of Oncology, 2014.
-
(2014)
Annals of Oncology
-
-
Smith, M.R.1
Coleman, R.E.2
Klotz, L.3
-
45
-
-
18644373689
-
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
-
T. Chen, J. Berenson, R. Vescio et al., "Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases, " Journal of Clinical Pharmacology, vol. 42, no. 11, pp. 1228-1236, 2002.
-
(2002)
Journal of Clinical Pharmacology
, vol.42
, Issue.11
, pp. 1228-1236
-
-
Chen, T.1
Berenson, J.2
Vescio, R.3
-
46
-
-
84870862207
-
Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a randomized phase II trial
-
K. Fizazi, L. Bosserman, G. Gao, T. Skacel, and R. Markus, "Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial, " Journal of Urology, vol. 189, no. 1, pp. S51-S58, 2013.
-
(2013)
Journal of Urology
, vol.189
, Issue.1
, pp. S51-S58
-
-
Fizazi, K.1
Bosserman, L.2
Gao, G.3
Skacel, T.4
Markus, R.5
-
47
-
-
0042331464
-
A doubleblind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)
-
D. P. Dearnaley, M. R. Sydes, M. D. Mason et al., "A doubleblind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial), " Journal of the National Cancer Institute, vol. 95, no. 17, pp. 1300-1311, 2003.
-
(2003)
Journal of the National Cancer Institute
, vol.95
, Issue.17
, pp. 1300-1311
-
-
Dearnaley, D.P.1
Sydes, M.R.2
Mason, M.D.3
-
48
-
-
84901944163
-
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (alliance)
-
M. R. Smith, S. Halabi, C. J. Ryan et al., "Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance), " Journal of Clinical Oncology, vol. 32, no. 11, pp. 1143-1150, 2014.
-
(2014)
Journal of Clinical Oncology
, vol.32
, Issue.11
, pp. 1143-1150
-
-
Smith, M.R.1
Halabi, S.2
Ryan, C.J.3
-
49
-
-
79952403539
-
Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases
-
N. K. Thudi, C. K. Martin, S. Murahari et al., "Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases, " Prostate, vol. 71, no. 6, pp. 615-625, 2011.
-
(2011)
Prostate
, vol.71
, Issue.6
, pp. 615-625
-
-
Thudi, N.K.1
Martin, C.K.2
Murahari, S.3
-
50
-
-
15444365985
-
Bone turnover mediates preferential localization of prostate cancer in the skeleton
-
A. Schneider, L. M. Kalikin, A. C. Mattos et al., "Bone turnover mediates preferential localization of prostate cancer in the skeleton, " Endocrinology, vol. 146, no. 4, pp. 1727-1736, 2005.
-
(2005)
Endocrinology
, vol.146
, Issue.4
, pp. 1727-1736
-
-
Schneider, A.1
Kalikin, L.M.2
Mattos, A.C.3
-
51
-
-
0344844468
-
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone
-
J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall, and E. T. Keller, "Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone, " Cancer Research, vol. 63, no. 22, pp. 7883-7890, 2003.
-
(2003)
Cancer Research
, vol.63
, Issue.22
, pp. 7883-7890
-
-
Zhang, J.1
Dai, J.2
Yao, Z.3
Lu, Y.4
Dougall, W.5
Keller, E.T.6
-
52
-
-
34447273333
-
Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical research council PR04 (ISRCTN61384873)
-
M. D. Mason, M. R. Sydes, J. Glaholm et al., "Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: medical research council PR04 (ISRCTN61384873), " Journal of the National Cancer Institute, vol. 99, pp. 765-776, 2007.
-
(2007)
Journal of the National Cancer Institute
, vol.99
, pp. 765-776
-
-
Mason, M.D.1
Sydes, M.R.2
Glaholm, J.3
-
53
-
-
21144438189
-
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
-
M. R. Smith, F. Kabbinavar, F. Saad et al., "Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, " Journal of ClinicalOncology, vol. 23, no. 13, pp. 2918-2925, 2005.
-
(2005)
Journal of ClinicalOncology
, vol.23
, Issue.13
, pp. 2918-2925
-
-
Smith, M.R.1
Kabbinavar, F.2
Saad, F.3
-
54
-
-
84922256444
-
Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: Efficacy and safety results of the Zometa European Study (ZEUS)
-
M. Wirth, T. Tammela, V. Cicalese et al., "Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS), " European Urology, 2014.
-
(2014)
European Urology
-
-
Wirth, M.1
Tammela, T.2
Cicalese, V.3
-
55
-
-
84937129011
-
Zometa European Study (ZEUS): Another failed crusade for the holy grail of prostate cancer bone metastases prevention?
-
B. Tombal, "Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention?" European Urology, 2014.
-
(2014)
European Urology
-
-
Tombal, B.1
-
56
-
-
84922255874
-
Reply from authors re: Bertrand tombal. Zometa european study (zeus): Another failed crusade for the holy grail of prostate cancer bone metastases prevention? Eur urol
-
zeus: the quest for the holy grail of prostate cancer bone metastases prevention continues
-
W. P. J. Witjes, A. Patel, and M. Wirth, "Reply from Authors re: Bertrand Tombal. Zometa European Study (ZEUS): another Failed Crusade for the Holy Grail of Prostate Cancer Bone Metastases Prevention? Eur Urol. In press. http://dx. doi. org/ 10. 1016/j. eururo. 2014. 03. 009. ZEUS: The Quest for the Holy Grail of Prostate Cancer Bone Metastases Prevention Continues, " European Urology, 2014.
-
(2014)
European Urology
-
-
Witjes, W.P.J.1
Patel, A.2
Wirth, M.3
-
57
-
-
84906940239
-
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03. 04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer
-
J. W. Denham, M. Nowitz, D. Joseph et al., "Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03. 04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer, " BJU International, vol. 114, no. 3, pp. 344-353, 2014.
-
(2014)
BJU International
, vol.114
, Issue.3
, pp. 344-353
-
-
Denham, J.W.1
Nowitz, M.2
Joseph, D.3
-
58
-
-
84855516339
-
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebocontrolled trial
-
M. R. Smith, F. Saad, R. Coleman et al., "Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebocontrolled trial, " The Lancet, vol. 379, no. 9810, pp. 39-46, 2012.
-
(2012)
The Lancet
, vol.379
, Issue.9810
, pp. 39-46
-
-
Smith, M.R.1
Saad, F.2
Coleman, R.3
-
59
-
-
84891687896
-
Denosumab and bone metastasis-free survival in men with nonmetastatic castrationresistant prostate cancer: Exploratory analyses by baseline prostate-specific antigen doubling time
-
M. R. Smith, F. Saad, S. Oudard et al., "Denosumab and bone metastasis-free survival in men with nonmetastatic castrationresistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time, " Journal of Clinical Oncology, vol. 31, no. 30, pp. 3800-3806, 2013.
-
(2013)
Journal of Clinical Oncology
, vol.31
, Issue.30
, pp. 3800-3806
-
-
Smith, M.R.1
Saad, F.2
Oudard, S.3
-
60
-
-
84907479141
-
Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone
-
P. D. Ottewell, N. Wang, J. Meek et al., "Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone, " Endocrine Related Cancer, vol. 21, no. 5, pp. 769-781, 2014.
-
(2014)
Endocrine Related Cancer
, vol.21
, Issue.5
, pp. 769-781
-
-
Ottewell, P.D.1
Wang, N.2
Meek, J.3
-
61
-
-
84908575897
-
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: Results from the randomised, phase 3 AFFIRM trial
-
K. Fizazi, H. I. Scher, K. Miller et al., "Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial, " The Lancet Oncology, vol. 15, no. 10, pp. 1147-1156, 2014.
-
(2014)
The Lancet Oncology
, vol.15
, Issue.10
, pp. 1147-1156
-
-
Fizazi, K.1
Scher, H.I.2
Miller, K.3
-
62
-
-
84870243969
-
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients withmetastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial
-
C. J. Logothetis, E. Basch, A. Molina et al., "Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients withmetastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial, " The Lancet Oncology, vol. 13, no. 12, pp. 1210-1217, 2012.
-
(2012)
The Lancet Oncology
, vol.13
, Issue.12
, pp. 1210-1217
-
-
Logothetis, C.J.1
Basch, E.2
Molina, A.3
-
63
-
-
84901638475
-
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial
-
O. Sartor, R. Coleman, S. Nilsson et al., "Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial, " The Lancet Oncology, vol. 15, no. 7, pp. 738-746, 2014.
-
(2014)
The Lancet Oncology
, vol.15
, Issue.7
, pp. 738-746
-
-
Sartor, O.1
Coleman, R.2
Nilsson, S.3
-
64
-
-
84937141223
-
Time to first skeletalrelated event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis
-
R. Coleman, S. Fossa, A. Chodacki et al., "Time to first skeletalrelated event (SRE) with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases: ALSYMPCA trial stratification factors analysis, " European Journal of Cancer, vol. 49, pp. S688-S688, 2013.
-
(2013)
European Journal of Cancer
, vol.49
, pp. S688-S688
-
-
Coleman, R.1
Fossa, S.2
Chodacki, A.3
-
65
-
-
84905170852
-
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study
-
M. R. Smith, C. J. Sweeney, P. G. Corn et al., "Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study, " Journal of Clinical Oncology, vol. 32, pp. 3391-3399, 2014.
-
(2014)
Journal of Clinical Oncology
, vol.32
, pp. 3391-3399
-
-
Smith, M.R.1
Sweeney, C.J.2
Corn, P.G.3
-
67
-
-
84898893682
-
Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial)
-
abstract 7
-
R. Dreicer, R. Jones, S. Oudard et al., "Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial), " Journal of Clinical Oncology, vol. 32, supplement 4, abstract 7, 2014.
-
(2014)
Journal of Clinical Oncology
, vol.32
-
-
Dreicer, R.1
Jones, R.2
Oudard, S.3
-
68
-
-
84937136206
-
Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC4 trial)
-
R. De Wit, K. Fizazi, V. Jinga et al., "Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC4 trial), " in Proceedings of the American Society of Clinical Oncology Meeting (ASCO '14), 2014.
-
(2014)
Proceedings of the American Society of Clinical Oncology Meeting (ASCO '14)
-
-
De Wit, R.1
Fizazi, K.2
Jinga, V.3
|